Vibliome Therapeutics

Vibliome Therapeutics, Inc. has discovered a new systematic approach to developing small molecule kinase inhibitors with unique selectivity profiles, and in some cases, extraordinary selectivity. With over 500 kinases in the human genome, they control nearly all cellular functions by transferring polar phosphate groups from ATP to serine, threonine, or tyrosine residues on regulatory proteins. The versatility of our chemistry platform provides numerous opportunities for variation while maintaining a common overarching architecture.